Novartis wins FDA approval for prostate cancer therapy

Mar. 23, 2022 4:20 PM ETNovartis AG (NVS)By: Dulan Lokuwithana, SA News Editor1 Comment

Novartis

TBE/iStock Editorial via Getty Images

  • On Wednesday, the U.S. Food and Drug Administration (FDA) granted the approval for Swiss pharma giant, Novartis (NYSE:NVS) to market its radioligand therapeutic agent Pluvicto as a treatment for certain adult patients

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.